Published in Eur J Nucl Med Mol Imaging on September 01, 2007
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol (2016) 1.32
Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging (2014) 1.26
Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging (2012) 1.12
Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol (2015) 1.04
From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro Oncol (2015) 0.99
The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro Oncol (2015) 0.95
Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET. Eur J Nucl Med Mol Imaging (2011) 0.87
Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas. Eur Radiol (2015) 0.83
Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas? Eur J Nucl Med Mol Imaging (2017) 0.80
Radiation injury vs. recurrent brain metastasis: combining textural feature radiomics analysis and standard parameters may increase (18)F-FET PET accuracy without dynamic scans. Eur Radiol (2016) 0.77
Amino Acid PET - An Imaging Option to Identify Treatment Response, Posttherapeutic Effects, and Tumor Recurrence? Front Neurol (2016) 0.76
The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin (2016) 0.76
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET. EJNMMI Res (2017) 0.75
Simultaneous 11C-Methionine Positron Emission Tomography/Magnetic Resonance Imaging of Suspected Primary Brain Tumors. PLoS One (2016) 0.75
[Molecular imaging in neurological diseases]. Radiologe (2016) 0.75
Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 2.42
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J (2002) 1.66
Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med (1999) 1.63
Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology (2002) 1.39
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging (2005) 1.20
Imaging in neurooncology. NeuroRx (2005) 1.14
[11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol (2006) 1.03
Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging (2006) 0.92
Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med (2001) 0.76
Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature (2006) 9.31
Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet (2006) 7.33
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet (2008) 3.94
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 3.90
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Palliative sedation: a review of the research literature. J Pain Symptom Manage (2008) 3.16
Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data. Eur J Nucl Med Mol Imaging (2003) 2.77
Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet (2011) 2.74
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther (2007) 2.64
Visualizing out-of-body experience in the brain. N Engl J Med (2007) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Status gelasticus after temporal lobectomy: ictal FDG-PET findings and the question of dual pathology involving hypothalamic hamartomas. Epilepsia (2005) 2.43
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res (2006) 2.23
Optimized in vivo detection of dopamine release using 18F-fallypride PET. J Nucl Med (2012) 2.18
Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma (2008) 2.12
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
HIF-1A, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys (2002) 2.00
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95
Lateral head impacts and protection of the temporal area by bicycle safety helmets. J Trauma (2007) 1.94
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab (2008) 1.94
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol (2009) 1.92
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology (2010) 1.78
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Hum Mol Genet (2006) 1.68
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med (2009) 1.65
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol (2004) 1.65
PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol (2002) 1.59
Regional brain activation during proximal stomach distention in humans: A positron emission tomography study. Gastroenterology (2005) 1.58
Cyclicity of spontaneous recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol (2007) 1.55
Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther (2009) 1.54
Longitudinal microPET imaging of brain glucose metabolism in rat lithium-pilocarpine model of epilepsy. Exp Neurol (2009) 1.52
Synthesis and biologic evaluation of (11)c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters. J Nucl Med (2003) 1.51
Clinical significance of heterotopic ossification in cervical disc replacement: a prospective multicenter clinical trial. Neurosurgery (2005) 1.49
EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging (2009) 1.49
Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry (2011) 1.48
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage (2013) 1.48
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol (2010) 1.48
Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2002) 1.45
Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol (2007) 1.42
HMGA2 regulates transcription of the Imp2 gene via an intronic regulatory element in cooperation with nuclear factor-kappaB. Mol Cancer Res (2007) 1.42
Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain (2008) 1.41
Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage (2009) 1.41
The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol (2007) 1.41
The Bryan Cervical Disc: wear properties and early clinical results. Spine J (2004) 1.41
Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest (2005) 1.41
Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum (2006) 1.37
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer (2011) 1.36
[(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging (2003) 1.35
Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomographic findings. Clin Nucl Med (2002) 1.35
Longitudinal prospective long-term radiographic follow-up after treatment of single-level cervical disk disease with the Bryan Cervical Disc. Neurosurgery (2010) 1.34
EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin Cancer Res (2007) 1.33
Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci (2010) 1.31
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS. Neurobiol Aging (2008) 1.31
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging (2004) 1.30
Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer (2013) 1.29
Characterization of pinhole SPECT acquisition geometry. IEEE Trans Med Imaging (2003) 1.27
Array CGH analysis in primary gastrointestinal stromal tumors: cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes Cancer (2007) 1.27
Accuracy of MRI in characterization of soft tissue tumors and tumor-like lesions. A prospective study in 548 patients. Eur Radiol (2004) 1.26
Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol (2005) 1.25
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother (2012) 1.24
Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer (2002) 1.24
Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging (2006) 1.24
Genome-wide analysis of Ollier disease: Is it all in the genes? Orphanet J Rare Dis (2011) 1.24
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol (2009) 1.23
Extramammary myofibroblastoma is genetically related to spindle cell lipoma. Virchows Arch (2006) 1.21
A dual-targeting anticancer approach: soil and seed principle. Radiology (2011) 1.21
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. Neuroimage (2004) 1.21
Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol (2008) 1.20
Evaluation of three MRI-based anatomical priors for quantitative PET brain imaging. IEEE Trans Med Imaging (2011) 1.20
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Gastrointestinal stromal tumor of the prostate. Urology (2005) 1.19
Primary peripheral PNET/Ewing's sarcoma of the dura: a clinicopathologic entity distinct from central PNET. Mod Pathol (2002) 1.19